Overview of N-(phosphonacetyl)-L-asparate + fluorouracil in clinical trials Journal Article
| Authors: | Martin, D. S.; Kemeny, N. E. |
| Article Title: | Overview of N-(phosphonacetyl)-L-asparate + fluorouracil in clinical trials |
| Abstract: | The clearest example of successful biochemical modulation of cancer chemotherapy in the laboratory, followed by initial failure to reproduce successful therapeutic results in the clinic, and then eventually followed by clinical success, is that of the combination of N-(phosphonacetyl)-l-asparate (PALA) and fluorouracil (5-FU). This review covers the biochemistry involved, the preclinical findings, the many clinical trials, and explains the differences between the initial unsuccessful and the later successful clinical studies. The overall findings demonstrate that, to be successful, the design of modulation-based clinical trials should adhere to the principles determined in preclinical studies. © 1992. |
| Keywords: | review; fluorouracil; cancer combination chemotherapy; drug potentiation; nonhuman; neurotoxicity; colorectal cancer; liver toxicity; bone marrow suppression; antimetabolites, antineoplastic; antineoplastic combined chemotherapy protocols; drug administration schedule; antineoplastic activity; drug synergism; gastrointestinal toxicity; cancer regression; drug mechanism; forecasting; aspartic acid; clinical trials; uridine; intravenous drug administration; phosphonoacetic acid; maximum permissible dose; sparfosic acid; human; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; acyclouridine derivative |
| Journal Title: | Seminars in Oncology |
| Volume: | 19 |
| Issue: | 2 Suppl. 3 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1992-04-01 |
| Start Page: | 228 |
| End Page: | 233 |
| Language: | English |
| PUBMED: | 1557654 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
